AffiliationDepartment of Rheumatology, Waterford Regional Hospital, Waterford, Ireland,, email@example.com.
MetadataShow full item record
CitationRheumatol Int. 2012 Jan;32(1):33-7. Epub 2010 Jul 24.
AbstractThe outlook of inflammatory joint diseases has changed significantly with the advent of TNF blockers. However, these advances come with a trade off-risk of infections, especially tuberculosis. The Irish society of rheumatology has proposed guidelines to investigate and treat latent TB infection (LTBI), which is in accordance with majority of international recommendations. This protocol requires that every patient with LTBI should have chemoprophylaxis. INH and different anti-rheumatic drugs are known to cause hepatic and gastrointestinal complications. We sought to investigate the toxicity of adding prophylactic anti-TB medications to different DMARDs and anti-TNF agents. We prospectively documented the course of all patients who were prescribed chemoprophylaxis for LTBI, from August 2007 to August 2008. Arrangements were made for central re-issuing of prescription of INH or rifampicin, after reviewing monthly liver function tests and following telephone interview seeking presence of adverse events. Out of 132 patients who were commenced on different TNF blockers, only 23 patients (17%) were diagnosed with LTBI and were given prophylaxis as per recommended guidelines. Thirty-nine percent (9 out of 23) of patients discontinued INH because of adverse events. Primary reason for discontinuation in these 9 patients was as follows: 3 patients got marked transaminitis (transaminases >5 times the normal limit), 5 patients had non-resolving gastrointestinal intolerance (mainly nausea), and one patient developed non-resolving rash. We have found a significant number of our patients (39%) who could not continue anti-TB prophylaxis due to either gastrointestinal intolerance or hypertransaminesemia.
- Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
- Authors: Kurt OK, Kurt B, Talay F, Tug T, Soy M, Bes C, Hayran M
- Issue date: 2013 Oct
- Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
- Authors: Kwon M, Sung M, Kwon YJ, Song YG, Lee SW, Park MC, Park YB, Lee SK, Song JJ
- Issue date: 2014 Mar
- Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment.
- Authors: Bray MG, Poulain C, Dougados M, Gossec L
- Issue date: 2010 Mar
- Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
- Authors: Gray EL, Goldberg HF
- Issue date: 2016 Mar
- A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
- Authors: Lee CK, Wong SHV, Lui G, Tang W, Tam LS, Ip M, Hung E, Chen M, Wu JC, Ng SC
- Issue date: 2018 Jul 30